Repligen Corp

Repligen Corp Stock Forecast & Price Prediction

Live Repligen Corp Stock (RGEN) Price
$208.42

4

Ratings

  • Buy 3
  • Hold 1
  • Sell 0
Disclaimer : The analyst ratings and price forecast data are provided by Tradefeeds. The data is sourced from Wall Street analysts and other experienced experts. The figures presented are solely a forecast and not a guarantee of future price performance. The information presented is not a recommendation to buy or sell the stock.

Stock Price

$208.42

P/E Ratio

P/E Ratio not available for RGEN

Volume Traded Today

$578,100

Dividend

Dividends not available for RGEN

52 Week High/low

211.13/110.45

Repligen Corp Market Cap

$11.64B

🛑 Alert: These ten stocks could have higher potential than $RGEN 🛑

Before you buy RGEN you’ll want to see this list of ten stocks that have huge potential. Want to see if RGEN made the cut? Enter your email below

RGEN Summary

From what 4 stock analysts predict, the share price for Repligen Corp (RGEN) might decrease by 8.84% in the next year. This is based on a 12-month average estimation for RGEN. Price targets go from $175.00 to $210.00. The majority of stock analysts believe RGEN is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

RGEN Analyst Ratings

RGEN is a stock in Health Care which has been forecasted to be worth $190.00 as an average. On the higher end, the forecast price is $210.00 USD by rachel vatnsdal from J.P. Morgan and on the lower end RGEN is forecasted to be $175.00 by timothy daley from Wells Fargo.

RGEN stock forecast by analyst

Analyst/Firm

Rating

Price Target

Change

Date

matt hewitt
Craig-Hallum

Buy

None

rated

Feb 16, 2024
paul knight
KeyBanc

Buy

$220.0

maintained

Feb 15, 2024
conor mcnamara
RBC Capital

Buy

$200.0

maintained

Jan 24, 2024
rachel vatnsdal
J.P. Morgan

Buy

$210.0

maintained

Dec 20, 2023
justin bowers
Deutsche Bank

Hold

$175.0

maintained

Dec 18, 2023
puneet souda
Leerink Partners

Buy

$175.0

maintained

Dec 7, 2023
robert wasserman
Benchmark Co.

Hold

None

downgraded

Dec 4, 2023
timothy daley
Wells Fargo

Buy

$175.0

maintained

Nov 6, 2023
daniel arias
Stifel Nicolaus

Buy

$165.0

maintained

Nov 2, 2023
alexander nowak
Craig-Hallum

Buy

None

rated

Oct 2, 2023
jacob johnson
Stephens

Buy

$200.0

maintained

Aug 3, 2023
julia qin
J.P. Morgan

Buy

$220.0

maintained

May 2, 2023
brandon couillard
Jefferies

Hold

$170.0

maintained

Apr 28, 2022
hugo solvet
BNP Paribas

Buy

$330.0

initiatedcoverage

Oct 14, 2021
ram selvaraju
H.C. Wainwright

Buy

$240.0

reiterated

Jun 22, 2021
tycho peterson
J.P. Morgan

Buy

$215.0

maintained

Nov 5, 2020
joseph munda
First Analysis

Buy

$110.0

upgraded

Nov 1, 2019
tracy marshbanks
First Analysis

Buy

$110.0

upgraded

Nov 1, 2019
david westenberg
Piper Sandler

Buy

$65.0

upgraded

Dec 17, 2018
drew jones
Stephens

Buy

$65.0

reiterated

Nov 2, 2018

RGEN Company Information

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

RGEN
Repligen Corp (RGEN)

When did it IPO

1986

Staff Count

2,025

Country

United States

Sector/Industry

Healthcare/Medical Instruments & Supplies

CEO

Mr. Anthony J. Hunt

Market Cap

$11.64B

Repligen Corp(RGEN) Financial Data

In 2023, RGEN generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that RGEN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2019

N/A

Revenue From 2020

N/A

0.00 %
From Previous Year

Revenue From 2021

N/A

0.00 %
From Previous Year

Revenue From 2022

N/A

0.00 %
From Previous Year
  • Revenue TTM $669.8M
  • Operating Margin TTM -0.04%
  • Gross profit TTM $455.7M
  • Return on assets TTM 0.02%
  • Return on equity TTM 0.06%
  • Profit margin 0.17288%
  • Book value 35.65%
  • Market capitalisation $11.64B
  • Revenue for 2020 N/A
  • Revenue for 2021 N/A
  • Revenue for 2022 N/A
  • EPS this year 2.02
  • EPS next year N/A

Repligen Corp(RGEN) Latest News

... ...

Similar Stocks to Repligen Corp RGEN

🛑 Alert: These ten stocks could have higher potential than $RGEN 🛑

Before you buy RGEN you’ll want to see this list of ten stocks that have huge potential. Want to see if RGEN made the cut? Enter your email below

...

RGEN Frequently asked questions

The highest forecasted price for RGEN is $210.00 from rachel vatnsdal at J.P. Morgan.

The lowest forecasted price for RGEN is $175.00 from timothy daley from Wells Fargo

The RGEN analyst ratings consensus are 3 buy ratings, 1 hold ratings, and 0 sell ratings.